Royce & Associates’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67.1K | Buy |
+11,748
| New | +$53.3K | ﹤0.01% | 742 |
|
|
2026
Q1 | – | Sell |
-605,000
| Closed | -$3.72M | – | 795 |
|
|
2025
Q4 | $3.72M | Sell |
605,000
-65,000
| -10% | -$471K | 0.04% | 511 |
|
|
2025
Q3 | $4.84M | Buy |
+670,000
| New | +$3.98M | 0.05% | 476 |
|
|
2020
Q3 | – | Sell |
-3,157
| Closed | -$36K | – | 1107 |
|
|
2020
Q2 | $36K | Buy |
3,157
+287
| +10% | +$4.08K | ﹤0.01% | 1065 |
|
|
2020
Q1 | $41K | Buy |
2,870
+796
| +38% | +$16.8K | ﹤0.01% | 1032 |
|
|
2019
Q4 | $56K | Sell |
2,074
-191,088
| -99% | -$5.26M | ﹤0.01% | 1026 |
|
|
2019
Q3 | $5.53M | Buy |
193,162
+15,664
| +9% | +$456K | 0.05% | 465 |
|
|
2019
Q2 | $4.93M | Buy |
177,498
+35,267
| +25% | +$996K | 0.04% | 492 |
|
|
2019
Q1 | $4.72M | Buy |
142,231
+131,246
| +1,195% | +$4M | 0.04% | 519 |
|
|
2018
Q4 | $319K | Sell |
10,985
-56,788
| -84% | -$2.04M | ﹤0.01% | 956 |
|
|
2018
Q3 | $3.12M | Buy |
67,773
+225
| +0.3% | +$10K | 0.02% | 716 |
|
|
2018
Q2 | $2.52M | Buy |
67,548
+116
| +0.2% | +$3.92K | 0.02% | 775 |
|
|
2018
Q1 | $1.99M | Buy |
67,432
+40,043
| +146% | +$1.35M | 0.01% | 856 |
|
|
2017
Q4 | $941K | Buy |
27,389
+34
| +0.1% | +$1.15K | 0.01% | 984 |
|
|
2017
Q3 | $990K | Buy |
+27,355
| New | +$780K | 0.01% | 967 |
|
|
2016
Q4 | – | Sell |
-90,369
| Closed | -$1.86M | – | 1096 |
|
|
2016
Q3 | $1.86M | Sell |
90,369
-847,129
| -90% | -$21.5M | 0.01% | 824 |
|
|
2016
Q2 | $28.7M | Sell |
937,498
-347,200
| -27% | -$12.1M | 0.19% | 156 |
|
|
2016
Q1 | $48.1M | Sell |
1,284,698
-130,200
| -9% | -$4.91M | 0.3% | 87 |
|
|
2015
Q4 | $61.1M | Sell |
1,414,898
-856,770
| -38% | -$36.2M | 0.36% | 64 |
|
|
2015
Q3 | $85.1M | Sell |
2,271,668
-551,535
| -20% | -$19.6M | 0.45% | 40 |
|
|
2015
Q2 | $96M | Sell |
2,823,203
-580,997
| -17% | -$19.8M | 0.41% | 53 |
|
|
2015
Q1 | $121M | Sell |
3,404,200
-1,680,363
| -33% | -$60.1M | 0.46% | 43 |
|
|
2014
Q4 | $173M | Sell |
5,084,563
-3,821,502
| -43% | -$136M | 0.6% | 22 |
|
|
2014
Q3 | $344M | Sell |
8,906,065
-393,413
| -4% | -$14.7M | 1.16% | 3 |
|
|
2014
Q2 | $362M | Sell |
9,299,478
-136,235
| -1% | -$5.07M | 1.08% | 3 |
|
|
2014
Q1 | $323M | Sell |
9,435,713
-1,407,362
| -13% | -$43.6M | 0.95% | 6 |
|
|
2013
Q4 | $227M | Sell |
10,843,075
-163,500
| -1% | -$4.14M | 0.65% | 17 |
|
|
2013
Q3 | $259M | Buy |
11,006,575
+262,180
| +2% | +$7.45M | 0.77% | 9 |
|
|
2013
Q2 | $289M | Buy |
+10,744,395
| New | +$311M | 0.89% | 9 |
|
Other funds holding MYGN
VPC
Royce & Associates's MYGN Position: Q2 2026 in Review
Royce & Associates opened a new position in Myriad Genetics (MYGN) in Q2 2026: 11,748 shares worth $67.1K. The stake represents ﹤0.01% of the portfolio and ranks #742 among its holdings. This is a return to the name: Royce & Associates previously reported a position in MYGN as recently as Q4 2025.
Royce & Associates first reported a position in MYGN in Q2 2013 and has held it in 29 quarters since. The position peaked at $362M in Q2 2014. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.
- Royce & Associates held 11,748 shares of Myriad Genetics worth $67.1K as of Q2 2026.
- Myriad Genetics was a new Royce & Associates position in Q2 2026.
- Myriad Genetics made up ﹤0.01% of Royce & Associates's portfolio in Q2 2026, its #742 holding.
- Royce & Associates first reported a position in Myriad Genetics in Q2 2013 and has held it in 29 quarters since.
- Royce & Associates's Myriad Genetics position peaked at $362M in Q2 2014.
- 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.
Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.